The United States District Court For The Northern District Of Illinois receives a class action complaint against a pay-for-delay agreement (Abbvie)

Plaintiffs Targeting Biologic-Biosimilars Settlements with Pay-for-Delay Antitrust Claims* Antitrust principles that can invalidate certain pay-for-delay settlements will be expanding into the new frontier of biologic and biosimilar drugs if plaintiffs in several new suits are successful. Recently-filed antitrust lawsuits against AbbVie, manufacturer of a leading biologic drug, Humira, and numerous biosimilar manufacturers are alleging that settlements between the AbbVie and various biosimilar competitors should be scrutinized under the principles of the Supreme Court’s Actavis decision. If the Northern District of Illinois agrees with the various allegations made by plaintiff classes, Actavis’s “large and unjustified” settlement payment standard could be expanded beyond the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Constantine Cannon (Washington)

Quotation

James Kovacs, The United States District Court For The Northern District Of Illinois receives a class action complaint against a pay-for-delay agreement (Abbvie), 18 March 2019, e-Competitions Bulletin May 2019, Art. N° 90345

Visites 22

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues